

AMENDMENT

Amendments to the Claims:

1.-35. (Canceled)

36-39. (Canceled)

40. (Currently Amended) ~~The~~An isolated hyperimmune serum-reactive antigen ~~or fragment of claim 36, comprising an amino acid sequence consisting of SEQ ID NO:91 or a fragment of at least 8 contiguous amino acids of SEQ ID NO:91.~~

41. (Currently Amended) The isolated hyperimmune serum-reactive antigen or fragment of claim [[36]]~~40~~, comprising at least 10 contiguous amino acids of SEQ ID NO:91.

42. (Canceled)

43. (Currently Amended) A pharmaceutical composition comprising an isolated hyperimmune serum-reactive antigen or fragment of claim [[36]]~~40~~.

44. (Canceled)

45. (Currently Amended) The pharmaceutical composition of claim 43, ~~further defined as~~ comprising at least two different isolated hyperimmune serum-reactive antigens and/or fragments.

46. (Canceled)

47. (Previously Presented) The pharmaceutical composition of claim 43, further comprising an immunostimulatory substance.

48. (Previously Presented) The pharmaceutical composition of claim 47, wherein the immunostimulatory substance is a polycationic polymer, an immunostimulatory deoxynucleotide (ODN), a peptide containing at least two LysLeuLys motifs, a neuroactive compound, alum, or a Freund's complete or incomplete adjuvant.

49. (Previously Presented) The pharmaceutical composition of claim 48, wherein the polycationic polymer is a polycationic peptide.

50. (Previously Presented) The pharmaceutical composition of claim 48, wherein the neuroactive compound is human growth hormone.

51-52. (Canceled)

53. (Withdrawn) A method of vaccinating a subject comprising:
obtaining a pharmaceutical composition of claim 43; and
administering the pharmaceutical composition to a subject;
wherein the subject is vaccinated.

54. (Withdrawn) The method of claim 53, wherein the subject is a human.

55. (Withdrawn) The method of claim 53, further defined as a method of treating and/or preventing *C. pneumoniae* infection in the subject.

56. (Withdrawn) The method of claim 53, wherein the hyperimmune serum-reactive antigen or fragment is directed against *C. pneumoniae*.

57. (New) A vaccine formulation comprising the pharmaceutical composition of claim 43.

58. (New) The isolated hyperimmune serum-reactive antigen of claim 40, wherein the hyperimmune serum-reactive antigen consists of SEQ ID NO:91.

59. (New) An isolated hyperimmune serum reactive antigen comprising an amino acid sequence consisting of amino acids 1-9, 4-10, 15-23, 16-28, 3-14, 16-30, 2-14, or 2-16 of SEQ ID NO:91.

60. (New) The isolated hyperimmune serum-reactive antigen of claim 59, wherein the isolated hyperimmune serum reactive antigen consists of amino acids 4-10, 16-28, 3-14, 16-30, 2-14, or 2-16 of SEQ ID NO:91.

61. (New) The isolated hyperimmune serum reactive antigen of claim 59, wherein the isolated hyperimmune serum reactive antigen consists of amino acids 1-9, 4-10, 15-23, 16-28, 3-14, 16-30 or 2-16 of SEQ ID NO:91.